Back to library
PharmaceuticalApproved

Minoxidil

MIN-ok-si-dil

Research profile · How we handle evidence

Category

Pharmaceutical

Compound type

Phase / Status

Approved

FDA approved for hair loss (topical)

Standard Dose

5% topical once daily or twice daily (product-dependent)

As directed (follow the specific product label)

Half-life

~4 hours (oral pharmacokinetics; topical effects differ)

Plasma elimination

Route(s)

OR / TO

Oral or Topical

Research Stage

Market Approved

Regulatory approval granted; post-market monitoring ongoing.

Overview

Minoxidil (often known from Rogaine) helps hair follicles stay in the growing (anagen) phase for longer. In plain terms: it increases blood flow/signaling to the follicle and makes it more likely that thinner, miniaturized hairs can grow back. It's used topically (foam or liquid), usually twice daily. Results typically take months, and an early 'shedding' period can happen - this is usually a normal part of the cycle shift rather than a failure. When you stop, benefits generally fade over time.

Plain-language summary

Minoxidil (often known from Rogaine) helps hair follicles stay in the growing (anagen) phase for longer. In plain terms: it increases blood flow/signaling to the follicle and makes it more likely that thinner, miniaturized hairs can grow back. It's used topically (foam or liquid), usually twice daily. Results typically take months, and an early 'shedding' period can happen - this is usually a normal part of the cycle shift rather than a failure. When you stop, benefits generally fade over time.

Administration Routes

  • Oral
  • Topical

Also known as

RogaineRegaineMinoxOral MinoxOMHair regrowth treatmentLonitenKirkland Minoxidil

Mechanisms

1

Topical vasodilator; potassium-channel opener (mitigates follicle miniaturization); prolongs anagen phase

Detailed mechanism

Minoxidil is converted to its active metabolite(s) in tissues. It acts as a potassium-channel opener and can increase signaling/blood flow effects around the follicle. These changes are associated with prolonged anagen duration and reduced follicle miniaturization in androgenetic alopecia.

Safety

Side effects

  • Scalp irritation (dryness, itching, redness) or dermatitis (topical)
  • Initial shedding during early treatment (often transient)
  • Unwanted hair growth in nearby areas (if it spreads)
  • Headache or dizziness

Reported benefits

  • Slows androgenetic hair loss
  • May increase hair density/thickness
  • Can help revive miniaturized follicles (best in early thinning)

Safety profile

Topical minoxidil is generally well tolerated, but irritation and early shedding are common. Seek medical advice promptly if you experience chest pain, fainting, rapid heartbeat, or significant dizziness.

Clinical trials

Ongoing/archived studies support efficacy for topical androgenetic alopecia; topical labeling is the primary reference.

Structure

View 3D structure

Verified structure

Minoxidil

Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.

Verified via PubChemMatched by casNumber
Source: PubChemLookup: 38304-91-5InChIKey ZIMGGGWCDYVHOY-UHFFFAOYSA-N
Chemical Formula
C9H15N5O
Molecular Weight
209.25 g/mol
CAS Number
38304-91-5
InChIKey
ZIMGGGWCDYVHOY-UHFFFAOYSA-N

Stack Context

No stack data available.

References

  1. 1

    Minoxidil mechanism of action in androgenetic alopecia (Journal of the American Academy of Dermatology)

    2007

    View source
  2. 2

    Oral vs topical minoxidil for hair loss: systematic review (PubMed)

    2022

    View source
  3. 3

    Minoxidil and its use in hair disorders: a review (Drug Design, Development and Therapy)

    2019

    View source

This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.

Research-driven insights.Evidence-based decisions.